Vuong Trieu, PhD
Founder of IgDraSol and Biomiga Diagnostics. Led the development of Cynviloq, Abraxane, nab-docetaxel, nab-rapamycin, nab-17-AAG, nab-IDN5404 at Abraxis (Celgene acquired Abraxis for $2.9 billion). Repositioned Genexol-PM from Korea into a viable product for US market as Abraxane equivalent and as drug-device combination therapy at IgDraSol
Larn Hwang, PhD
Drug developer veteran with broad expertise in drug discovery and biomarker development. Key strength on drug discovery/development, clinical and regulatory operations. Led the team through a successful EOP2 meeting and FPI within 4 months of protocol. Founder of IgDraSol and Biomiga Diagnostics.
J&J, ABI, Celgene, IgDraSol, Biomiga Diagnostics, Sorrento Therapeutics
Chulho Park, PhD
Recognized pharmaceutical leader in Korea with strong business development background. Leader in the field of mAb engineering. CEO and Founder of MabPrex. Led the pharmaceutical development of therapeutic antibodies as well as small molecule drugs. President of Pharmaceutical Development at Igdrasol. Led the CMC deveopment at IgDraSol bringing manufacturing of the drug product to US FDA standard.
Eli Lilly, AME, aTyr, MabPrex, IgDraSol